Combined Q1 Revenue of 111 Pharmaceutical Companies on the SSE Main Board Exceeds RMB 330.5 Billion

Data shows that a total of 111 pharmaceutical companies on the SSE Main Board achieved a combined operating revenue of RMB 330.55 billion in the Q1 2026, representing a 2% year-on-year increase. Their combined net profit reached RMB 24.7 billion, up 0.5% year-on-year.

Among them, WuXi AppTec and Hengrui Pharmaceuticals contributed net profits exceeding RMB 4.65 billion and RMB 2.28 billion, respectively. Both companies achieved significant growth in both quarterly revenue and net profit, providing strong support for the industry's overall performance in Q1.